Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. 2004. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Researchs 24(5a) P.2783-840.
Ali S, Watson MS, Osborne RH. 2004. The stimulant cathartic, emodin, contracts the rat isolated ileum by triggering release of endogenous acetylcholine. Autonomic & Autacoid Pharmacology 24(4) P. 103-105.
Andlauer W, Kolb J, Siebert K, Furst P. 2000. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Under Experimental and Clinical Research 26(2) P.47-55.
Anzai N, Kanai Y, Endou H. 2006. Organic anion transporter family: current knowledge. Journal of Pharmacological Sciences 100(5) P.411-426.
Assaraf YG. 2006. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resistance Updates 9(4-5) 227–246.
Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Mérillon JM, Magdalou J, Sabolovic N. 2001. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Archives of Biochemistry and Biophysics 393(2) P. 281–289.
atori N, Hammond CL, Cunningham JB, Krance SM, Marchan R. 2005 Molecular mechanisms of reduced glutathione transport: role of the MRP/CFTR/ABCC and OATP/SLC21A families of membrane proteins. Toxicology and applied pharmacology 204(3) P.238-55
Baur JA, Sinclair DA. 2006. Therapeutic potential of resveratrol: the in vivo evidence. Drug Discovery 5(6) P. 493-506.
Borst P, Zelcer N, van de Wetering K. 2006. MRP2 and 3 in health and disease. Cancer Letters 234(1) P.51-61.
Chan LM, Lowes S, Hirst BH. 2004. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. European Journal of Pharmaceutical Sciences. 21(1) P.25-51.
Chang JS, Liu HW, Wang KC, Chen MC, Chiang LC, Hua YC, Lin CC. 2005. Ethanol extract of polygonum cuspidatum inhibits hepatitis B virus in a stable hbv-producing cell line. Antiviral Research 66(1) P.29-34.
Chang LC, Sheu HM, Huang YS, Tsai TR, Kuo KW. 1999. A novel function of emodin: enhancement of the nucleotide excision repair of UV- and cisplatin-induced DNA damage in human cells. Biochemical Pharmacology 58(1) P. 49–57.
Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD.
60
Chla ova
te in the
A, Liu R. 2005. Preparative isolation and purification of five
comp cc by
y SE, Braun MP, Sarkadi B, Evans DC, Evers R. 2004.
Trans
ulmonary function
in pat
of
medicine. Molecular Interventions 6(1) P.36-47.
of
er.
Xeno
phation
esent in grape and wine, in the human liver and
duode
ule for fighting cancer. Current Drug
Targe
f
plex virus vaginal infection in the mouse. Antiviral Research
67(3)
tion of herpes simplex virus replication. Antiviral Research 43(3)
P.135
pean Journal of Pharmaceutical Sciences 27(5) P. 501–517.
Feng
2003. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Molecular Pharmacology 63(2) P.351–358.
Cheng YW, Kang JJ. 1998. Emodin-induced muscle contraction of mouse diaphragm and the involvement of Ca2+ influx and Ca2+ release from sarcoplasmic reticulum. British Journal of Pharmacology. 123(5) P.815–820.
dek J, Grim J, Martinkova J, Simkova M, Vaniekova J, Koudelkova V, NoiekM. 2002. Pharmacokinetics and pharmacodynamics of low-dose methotrexatreatment of psoriasis. British Journal of Clinical Pharmacology 54(2) P.147-56.Chu X, Sun
ounds from the Chinese medicinal herb polygonum cuspidatum sieb. Et zuHigh-Speed Counter-Current chromatography. Journal Of Chromatography A 1097(1-2) P. 33–39. Chu XY, Huske
port of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. The Journal of Pharmacology and Experimental Therapeutics 309(1) P.156-64. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. 1996. P
ients receiving long-term low-dose methotrexate. Chest 109(4) P. 933-938.Das DK, Maulik N. 2006. Resveratrol in cardioprotection: a therapeutic promisealternative
De Santi C, Pietrabissa A, Mosca F, Pacifici GM. 2000a. Glucuronidationresveratrol, a natural product present in grape and wine, in the human liv
biotica 30(11) P.1047-1054. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. 2000b. Sulof resveratrol, a natural product pr
num. Xenobiotica 30(6) P.609-617. Delmas D, Lancon A, Colin D, Jannin B, Latruffe N. 2006. Resveratrol as a chemopreventive agent: a promising molec
t 7(4) P.423-442.Docherty JJ, Fu MM, Hah JM, Sweet TJ, Faith SA, Booth T. 2005. Effect oresveratrol on herpes sim
P.155-162. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL. 1999. Resveratrol inhibi
-145.Endres CJ, Hsiao P, Chung FS, Unadkat JD. 2006. The role of transporters in drug interactions. Euro
YH, Zhou WL, Wu QL, Li XY, Zhao WM, Zou JP. 2002. Low dose of
61
P. 893
ethotrexate. Immunopharmacology 47(2-3) P.247-257.
5.
apica od
al blood mononuclear cells, monocyte-derived
macro
erbs,
suppressive properties. European Journal of
Pharm
dicinal Research Reviews P.1-21.
integrin
signa
indings in nine patients.
Europ
onal 35(2) P.195-199.
sm by
gy 55(3)
P.307
ical
ics 7(11) P.1847-1858.
Kerb
234 (1) P.4-33.
ffect on platelet aggregation in
whol
from recent
resveratrol enhanced immune response of mice. Acta Pharmacologica Sinica 23(10)
-897.Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. 2000. Mechanismsof action of m
Henry C, Vitrac X, Decendit A, Ennamany R, Krisa S, Mérillon JM. 200Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the
l membrane of human intestinal caco-2 cells. Journal of Agricultural and FoChemistry 53(3) P. 798-803. Heredia A, Davis C, Redfield R. 2000. Synergistic inhibition of HIV-1 in activated and resting peripher
phages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. Journal of Acquired Immune Deficiency Syndromes 25(3) P.246-55. Huang Hc, Chu Sh, Chao-Lee Pd. 1991. Vasorelaxants from chinese hemodin and scoparone, possess immuno
acology 198(2-3) P.211-213. Huang Q, Lu G, Shen HM, Chung MC, Ong CN. 2006. Anti-cancer properties of anthraquinones from rhubarb. Me
Huang Q, Shen HM, Shui G, Wenk MR, Ong CN. 2006. Emodin inhibits tumor cell adhesion through disruption of the membrane lipid raft-associated
ling pathway. Cancer Research 66(11) P.5807-5815. Imokawa S, Colby TV, Leslie KO, Helmers RA. 2000. Methotrexate pneumonitis: review of the literature and histopathological f
ean Respiratory Journal 15(2) P.373-381. Juan ME, Buenafuente J, Casals I, Planas JM. 2002. Plasmatic levels of trans-resveratrol in rats. Food Research Internati
Kaldas MI, Walle UK, Walle T. 2003. Resveratrol transport and metabolihuman intestinal caco-2 cells. The Journal of pharmacy and pharmacolo
-12 Kennedy J. 2005. Herb and supplement use in the US adult population. ClinTherapeut
R. 2006. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Letters
Kirk RI, Deitch JA, Wu JM, Lerea KM. 2000. Resveratrol decreases early signaling events in washed platelets but has little e
e blood. Blood Cells, Molecules, and Diseases 26(2) P.144–150. Kruh GD, Belinsky MG, Gallo JM, Lee K. 2007. Physiological and pharmacological functions of MRP2, MRP3 and MRP4 as determined
62
studie 14.
2
Kuhn
sveratrol is absorbed in the small intestine as
resve
ydroxyanthraquinone) inhibits TNF-induced NF-kB activation,
IkB d roteins in human vascular
CG2) in tissue defense. Toxicology
and A
rnal of Ethnopharmacology 52(2) P.
107-1
Expert Opinion on Drug Metabolism & Toxicology 3(3) P.389-406
Man d
.727–
47.
and disposition of resveratrol in rats: extent of absorption,
glucu .
7.
e
amon
r family: properties and pharmacological significance. Trends In
Pharm
lopment. Pharmacological Reviews
55(3)
ge in male and female stroke-prone spontaneously hypertensive
s on gene-disrupted mice. Cancer and Metastasis Reviews 26(1) P.5–Kruh GD, Belinsky MG. 2003. The MRP family of drug efflux pumps. Oncogene 2(47) P.7537-7552.
le G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, Rice-Evans C, Hahn U. 2000. Re
ratrol glucuronide. Biochemical and Biophysical Research Communications. 272(1) P.212–217.Kumar A, Dhawan S, Aggarwal BB. 1998. Emodin (3-methyl-1,6,8-trih
egradation, and expression of cell surface adhesion pendothelial cells. Oncogene 17(7) P. 913-918. Leslie EM, Deeley RG, Cole SP. 2005. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (AB
pplied Pharmacology 204(3) P. 216-237. Lin CC, Chang CH, Yang JJ, Namba T, Hattori M. 1996. Hepatoprotective effects of emodin from ventilago leiocarpa. Jou
11. Liu Z, Hu M. 2007. Natural polyphenol disposition via coupled metabolic pathways.
ach C, Scalbert A, Morand C, Remesy C, Jimenez L. 2004. Polyphenols: foosources and bioavailability. The American Journal of Clinical Nutrition 79(5) P
Marier JF, Vachon P, Gritsas A, Zhang J, Moreau JP, Ducharme MP. 2002. Metabolism
ronidation, and enterohepatic recirculation evidenced by a linked-rat modelThe Journal of Pharmacology and Experimental Therapeutics 302(1) P.369–373. Marinac JS, Buchinger CL, Godfrey LA, Wooten JM, Sun C, Willsie SK. 200Herbal products and dietary supplements: a survey of use, attitudes, and knowledg
g older adults. The Journal of The American Osteopathic Association 107(1) P.13-20. Miyazaki H, Sekine T, Endou H. 2004. The multispecific organic anion transporte
acological Sciences 25(12) P.654-662. Mizuno N, Niwa T, Yotsumoto Y, Sugiyamap Y. 2003. Impact of drugtransporter studies on drug discovery and deve
P.425–461 Mizutani K, Ikeda K, Kawai Y, Yamori Y. 2001. Protective effect of resveratrol on oxidative dama
63
rats. C
. Chemical &
Pharm
. Biomedicine & pharmacotherapy
56(6)
terization of a novel multispecific organic anion transporter. The
Journ
itro by emodin. Medical
Scien
iators
lied Pharmacology 204(3) P.198-215.
eins
)
P.1-1
okinetics 17(4) P.253-274.
Van E te
th focus on mechanisms involved in toxicity.
Semi
. Journal of
Agric
but
and
Dispo
vitro. Chinese Medical Journal 115(3) P.378-80.
Nutri
trexate
linical and Experimental Pharmacology and Physiology 28(1-2) P.55-59. Ng KH, Lim BG, Wong KP. 2003. Sulfate conjugating and transport functionsof MDCK distal tubular cells. Kidney International 63(3) P. 976–986.
Qian G, Leung SY, Lu G, Leung KS. 2006. Differentiation of Rhizoma Et RadixPolygoni Cuspidati from closely related herbs by HPLC fingerprinting
aceutical Bulletin 54(8) P. 1179-1186. Scalbert A, Morand C, Manach C, Remesy C. 2002. Absorption and metabolismof polyphenols in the gut and impact on health
P. 276–282. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H. 1997. Expressioncloning and charac
al of Biological Chemistry 272(30) P.18526-18529. Shuangsuo D, Zhengguo Z, Yunru C, Xin Z, Baofeng W, Lichao Y, Yan''an C. 2006. Inhibition of the replication of hepatitis B virus in v
ce Monitor : International Medical Journal of Experimental And Clinical Research 12(9) P. Br302-306. Sweet DH. 2005. Organic anion transporter (SLC22A) family members as medof toxicity. Toxicology and App
Tian Q, Zhang J, Chan E, Duan W, Zhou S. 2005. Multidrug resistance prot(MRPs) and implication in drug development. Drug Development Research. 64(1
8. Tsuji A. 2002. Transporter-mediated drug interactions. Drug Metabolism and Pharmac
de AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. 1998. Methotrexain rheumatoid arthritis: an update wi
nars in Arthritis and Rheumatism 27(5) P.277-292.Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z, Rosen RT. 2000. Isolation and identification of stilbenes in two varieties of polygonum cuspidatum
ultural and Food Chemistry 48(2) P.253-256. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. 2004. High absorptionvery low bioavailability of oral resveratrol in humans. Drug Metabolism
sition 32(12) P.1377-1382. Wang Z, Zou J, Huang Y, Cao K, Xu Y, Wu JM. 2002. Effect of resveratrol onplatelet aggregation in vivo and in
Wenzel E, Soldo T, Erbersdobler H, Somoza V. 2005. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Molecular
tion & Food Research 49(5) P.482-494. Widemann BC, Adamson PC. 2006. Understanding and managing metho
64
Won
ournal of Natural Products 63(10) P.1373-1376.
inone as a
se
Medi
uto
emen RB. 2002. Human, rat, and mouse metabolism of
resve
ncer cells by emodin.
Canc
harmaceutical Research 24(1)
P.28-
染柯
毒大鼠心肌細胞保護作用的實驗研究。中國中醫藥科技 1(1) P.34-35。
30-233。
研究所，P.63-65。
江中醫學院學報 28(4)
P.60~
療急性上消化道出血的臨床研究，中國中醫藥科技 11(2) P.69-71。
大學醫
nephrotoxicity. Oncologist 11(6) P.694-703.
g JM, Esdaile JM. 2005. Methotrexate in systemic lupus erythematosus. Lupus 14(2) P.101–105.
Xiao K, Xuan L, Xu Y, Bai D. 2000. Stilbene glycoside sulfates from polygonum cuspidatum. J
Xiong WD, Ma QY. 2004. Study of chinese herbs containing anthraqukind of potential natural preservatives. Tianjin Journal of Traditional Chine
cine 2 P.158-160. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, PezzJM, Mehta RG, van Bre
ratrol. Pharmaceutical Research 19(12) P.1907-1914.Zhang L, Chang CJ, Bacus SS, Hung MC. 1995. Suppressed transformation andinduced differentiation of HER-2/neuoverexpressing breast ca
er Research 55(17) P. 3890-3896. Zhou F, You G. 2007. Molecular insights into the structure- function relationship of organic anion transporters oats. P
36. 申成華、鄭善子、崔春權、李太一，2005，虎杖水煎液對体外培養感薩奇B3病
曲洪林、李笑岩、王鳳英、紀象芹、商全梅， 2004，虎杖對缺氧性肺動脈高壓的作用及机制研究，濱州醫學院學報 27(5) P.328-329。
吳開雲、黃雪芳、彭宣憲，1996，冰片、虎杖、地榆抑菌作用的實驗研究，江西醫學院學報 36(2) P.53-55。
肖凱、宣利江、徐亞明、白東魯，2003，虎杖的化學成分研究，中國藥學雜誌 38(1) P.12-14。
張海防、竇昌貴、劉曉華、顧菲菲，2003，虎杖提取物抗炎作用的實驗研究，藥學進展27(4) P.2
張珮樺，碩士論文，大黃、大黃素之代謝動力學及其對環孢靈動力學之影響，2003，中國醫藥學院藥物化學傅志泉、雍定國、周智林、耿寶琴、劉云霞、楊麗姣、金亞城，2004，虎杖口服液抗胃出血及抗胃潰瘍作用的實驗研究，浙
61。 傅志泉、雍定國、周智林、耿寶琴、劉云霞、楊麗姣、金亞城，2004，虎杖口服液治
馮雷. 2003. 虎杖研究新進展. 醫藥論壇雜誌24(9) P.78-79。 裴蓮花、吳學、金光洙，2006，虎杖化學成分及藥理作用研究現狀，延邊
學學報 29(2) P.147-149。
劉曉秋、于黎明、吳立軍，2003，虎杖化學成分研究 (Ⅰ)，中國中藥雜誌
65
28(1) P.47-49。
薛嵐，2000，中藥虎杖的藥理研究進展，中國中藥雜誌 25(11) P.652-653。